A US advisory committee is reviewing whether seven injectable peptides should be added to the list of bulk drug substances that can be used in compounded medicines. The panel is discussing BPC-157, emideltide (DSIP), epitalon, KPV, MOTS-c, semax, and TB-500. At the moment, compounding pharmacies in the US are not allowed to produce any of these substances. Interest in the discussion has grown as gray market sales continue to expand and political support for wider access has increased.
Government scientists recently recommended against allowing the seven peptides to be compounded. Their review concluded that there is not enough evidence on safety or effectiveness, pointing to the limited number of human studies. The debate reflects a difference of opinion between scientific reviewers and political leadership over whether access should be expanded.
Experts in pharmacy compounding, online drug safety, and dermatology do not agree on whether the peptides should be approved. They do agree on one point. If access is allowed, strict safeguards should be introduced alongside any decision.
The committee’s recommendations are not binding, but they are expected to influence the final regulatory decision.
Gray market concerns
Peptides are short chains of amino acids that help build proteins and perform important biological functions. They have been used in topical skin care products since the 1990s. Injectable peptides have recently attracted much more public attention.
Once limited mainly to medical use, injectable peptides are now widely promoted in the wellness market. Social media influencers describe them as products that support longevity, anti-aging, skin rejuvenation, tissue repair, and body optimization. Unlike topical products, injectable peptides are promoted as providing direct systemic cellular support.
Many consumers now purchase injectable peptides through gray market sources.
One industry representative argues that gray market sales dominate peptide distribution because only research-grade active pharmaceutical ingredients are currently available. According to this view, there are no active ingredients produced under current good manufacturing practice standards.
Online drug safety specialists say the discussion must include internet sales. Concerns about purity, potency, sterility, and overall product quality exist wherever peptides are sold, but online platforms increase the speed, reach, and scale of those risks.
A consumer survey published in 2025 found that 65% of consumers incorrectly believe every website offering online prescription services has been reviewed or approved by regulators. Experts say this misunderstanding is especially worrying for injectable peptides, where sellers often use scientific language, “research use only” disclaimers, and cosmetic or wellness marketing to appear trustworthy.
Consumers are advised to be cautious of websites or social media accounts selling injectable peptides without prescriptions, making vague wellness claims, promising rapid results, or displaying “not for human use” disclaimers while clearly marketing to consumers.
The internet increases the risk because products can be promoted quickly, anonymously, and to large audiences. Consumers often have no way of knowing where products come from, whether they have been tested properly, or what options are available if something goes wrong.
Supporters of a regulated pathway believe that approval would encourage manufacturers to invest in pharmaceutical-grade production that follows current manufacturing standards. They argue that this would reduce demand for gray market products.
They acknowledge that the current situation is imperfect. Patients continue to seek products through illicit markets, creating what they describe as a public health concern that requires a different regulatory response.
Calls for safeguards
Supporters of approval want the seven injectable peptides added to the list of substances allowed for compounding. They argue that pharmaceutical-grade manufacturing infrastructure should be developed alongside any approval.
They recognize that their proposal is not ideal, but argue that ignoring the existing health risks linked to illicit markets is equally concerning.
Some believe stricter enforcement alone is unlikely to solve the problem. They argue that approving the peptides without safeguards would create problems, yet banning them completely would not eliminate demand or address the existing gray market.
Critics argue that approval could further normalize peptide use. Supporters believe building a regulated system is the more practical approach.
Online safety specialists maintain that patient safety should remain the priority. They recommend that regulators prevent any limited compounding pathway from being used to support wider internet sales.
Without clear oversight and enforcement, they warn that unsafe or unverified products could appear legitimate to consumers through regulatory uncertainty.
Patients, they argue, should not receive injectable products through wellness channels or the personal care market. Consumer demand should not be treated as evidence of safety.
Any final decision should clearly explain what is allowed, what remains prohibited, and how consumers and healthcare providers can identify regulated sources of approved medicines.
Cosmetic use and safety
Topical peptides have been studied for many years and have an established safety profile because they mainly act on the skin’s surface with minimal systemic exposure. Injectable peptides bypass the skin barrier and may carry risks including infection, allergic reactions, inconsistent dosing, and systemic effects.
Dermatology specialists say injectable peptides present different safety concerns from topical products, particularly when used for cosmetic purposes.
There is growing public interest in injectable peptides for skin health and anti-aging, yet the available scientific evidence remains limited. Marketing has moved faster than the research, leaving no clear standards and creating wide differences in sourcing.
Many patients ask about injectable peptides without proper medical supervision. Experts acknowledge that there may be potential benefits, but say there is still not enough research to support routine use.
Treatments should demonstrate both safety and effectiveness before being recommended. Consumers are advised to be cautious of anti-aging claims that are not supported by strong clinical evidence or appropriate regulatory oversight.
Safety specialists add that injectable products leave very little room for error. Purity, potency, and consistency remain critical concerns.
Recommended safeguards include ingredient sourcing, supplier qualification, identity testing, purity, potency, sterility, endotoxin testing, stability testing, labeling, and adverse event reporting.
These products should only be prepared under appropriate clinical oversight and with valid prescriptions. They should not be marketed as ordinary wellness products or sold online using unsupported claims.
Advice for consumers
Dermatology experts strongly advise against self-injecting peptides to improve the appearance of the skin, hair, or nails.
They point to the lack of human studies and long-term safety data. Many products have not been adequately evaluated for effectiveness, contamination, ingredient concentration, or manufacturing cleanliness because suppliers operate outside existing restrictions.
Claims of dramatic improvements in skin or hair are not considered worth the potential risks.
Reported concerns among people using injectable peptides obtained from unregulated gray market suppliers include unwanted skin pigmentation changes, infection, swelling, pain, redness, and new or changing moles.
Industry representatives state that there has not been an increase in adverse events linked to injectable peptides in the national adverse event reporting database or poison control reports. They still acknowledge that improperly prepared or contaminated injectable peptides can create serious patient safety risks.
Supporters argue that sterile injectable products prepared by licensed pharmacies in compliant clean rooms and supplied through valid prescriptions provide a safer alternative than gray market products for people who are already seeking these substances.
